Methylene Blue as a Third-line Vasopressor in Septic Shock

PHASE2UnknownINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

October 1, 2024

Study Completion Date

November 1, 2024

Conditions
Septic Shock
Interventions
DRUG

Methylene Blue

"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."

DRUG

Phenylephrine

"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."

Trial Locations (1)

24014

RECRUITING

Carilion Clinic, Roanoke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Provepharm Life Solutions

UNKNOWN

lead

Carilion Clinic

OTHER